AbbVie announces provincial reimbursement for Rinvoq (upadacitinib) for the treatment of rheumatoid arthritis and psoriatic arthritis in Alberta, New Brunswick, Ontario, Quebec and Saskatchewan

1 December 2022 - AbbVie today announced that Rinvoq is now listed as a special authorisation medication or exception medication status ...

Read more →

Livtencity (maribavir) receives positive CADTH recommendation for adults with post-transplant cytomegalovirus infection

1 December 2022 - The conditions for the positive recommendation is supported by the findings of the Phase 3 SOLSTICE ...

Read more →

Lenvatinib mesylate in combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma

30 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Capstone announces authorisation of biosimilar human insulin for IV infusion in Canada and EU

29 November 2022 -  Capstone announced today that a biosimilar version of human insulin received authorisation from the EMA's CHMP ...

Read more →

Health Canada has approved Sotyku (deucravacitinib tablets), an oral treatment for adults with moderate to severe plaque psoriasis

28 November 2022 - Sotyktu is the first and only approved TYK2 inhibitor in Canada and represents an important milestone ...

Read more →

GSK Canada submits respiratory syncytial virus vaccine candidate for regulatory review

25 November 2022 - Application includes important pivotal Phase 3 data evaluating the efficacy and safety of our vaccine candidate against ...

Read more →

Health Canada authorises Polivy (polatuzumab vedotin) for the first-line treatment of adults with large B-cell lymphoma

24 November 2022 - Authorization is based on pivotal data from the Phase 3 POLARIX trial, which met its primary ...

Read more →

Korea to add Canada, Australia to drug pricing reference country list

24 November 2022 - The Government said it would additionally reference Canada and Australia when setting drug prices from January ...

Read more →

Novavax’s COVID-19 booster has been approved for adults, Health Canada says

17 November 2022 - Health Canada said Thursday it has approved the booster dose of Novavax‘s Nuvaxovid COVID-19 vaccine for ...

Read more →

Canadian migraine sufferers have a new treatment option - Health Canada approves Ubrelvy (ubrogepant)

16 November 2022 - Ubrelvy is the first and only oral CGRP receptor antagonist (gepant) approved by Health Canada for the ...

Read more →

CADTH launches consultation on real world evidence reporting guidance

10 November 2022 - Today, CADTH, on behalf of the Real World Evidence Steering Committee, launched a public consultation to ...

Read more →

Implementation of the Patented Medicine Prices Review Board's proposed Guidelines will harm Canadian patients

10 November 2022 - Innovative Medicines Canada is calling on Health Canada to direct the Patented Medicine Prices Review Board (PMPRB) ...

Read more →

Health Canada approves Camzyos (mavacamten) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy

10 November 2022 - Camzyos is the only Health Canada approved reversible cardiac myosin inhibitor indicated for the treatment of ...

Read more →

Vabysmo (faricimab) receives positive CADTH recommendation for the treatment of diabetic macular oedema in adults

3 November 2022 - This CADTH recommendation is the latest step towards public access to Vabysmo (faricimab) for the estimated 60,000 ...

Read more →

New PMPRB guidelines proposed for assessing prices of patented medicines sold in Canada

4 November 2022 - Controversial amendments to the Patented Medicines Regulations changing the basket of comparator countries considered by the ...

Read more →